Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18259020 | ARTIFICIAL ANTIGEN-PRESENTING CELL | Non-Final OA | National University of Singapore |
| 18121285 | POLYCLONAL ANTIBODY TARGETING SODIUM ION CHANNEL, PHARMACEUTICAL COMPOSITION COMPRISING POLYCLONAL ANTIBODY TARGETING SODIUM ION CHANNEL, AND METHOD FOR TREATING AND/OR PREVENTING CARDIAC ARRHYTHMIA BY USING POLYCLONAL ANTIBODY TARGETING SODIUM ION CHANNEL | Non-Final OA | National Taiwan University |
| 18262287 | BI-SPECIFIC CAR T CCELLS FOR B CELL MALIGNANCIES | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18187960 | CHEMERIN INHIBITORS AND USES THEREOF FOR TREATING KIDNEY CANCER | Non-Final OA | University of Miami |
| 18296591 | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS | Non-Final OA | Xencor, Inc. |
| 18188406 | ANTI-CD83 CAR-T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION | Non-Final OA | CRISPR Therapeutics AG |
| 18353565 | Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response | Non-Final OA | Gadeta B.V. |
| 18261158 | NOVEL ALLERGEN ISOFORM VARIANTS | Non-Final OA | PHADIA AB |
| 18311409 | MURINE ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER | Non-Final OA | Pell Bio-Med Technology Co., Ltd. |
| 18140403 | CHEMOGENETIC RECEPTORS AND METHODS OF MAKING AND USING | Non-Final OA | Howard Hughes Medical Institute |
| 18122273 | Anti-netrin-1 antibody to treat liver inflammation | Non-Final OA | NETRIS PHARMA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy